Douglas Dynamics, Inc.

Freedom Broker recommends clients buy shares of Douglas Dynamics, a small manufacturer of snow-clearing equipment whose stock is up more than 30% year to date. The target price set for Douglas securities is 20% above current quotes. Sustainable growth is supported by well-known brands, a wide dealer network, and a balanced sales structure, analysts say.

Freedom initiates on snowplow maker Douglas with 'buy,' TP implying 20% upside

NVIDIA Corporation

Microsoft Corporation

The Boeing Company

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: the Fed is on the ropes

Unitil Corporation

Global Water Resources, Inc.

Sky Harbour Group Corporation

Millrose Properties, Inc.

Industrial Logistics Properties Trust

The Fed will announce its interest-rate decision on Wednesday, October 29. Markets <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">expect</a>&nbsp;a 25-basis-point cut to 3.75-4.00%. The prior revision in September reignited the stock market, and analysts <a href="https://en.oninvest.com/article/russell-2000-is-clear-winner-from-fed-rate-cut-reaches-new-all-time-high">called</a>&nbsp;small-caps – represented by the Russell 2000 index – the “clear winner.” The day after the decision, on September 18, the index hit a new all-time high for the first time in four years, jumping 2%. Over the last six months, the <a href="https://finance.yahoo.com/quote/%5ERUT/">Russell 2000</a>&nbsp;is up 28.4%, outpacing the <a href="https://finance.yahoo.com/quote/%5ESPX/">S&amp;P 500</a>, the benchmark for large caps, which is up 23.8% in the same period.

Freedom picks small caps set to gain from another Fed rate cut

Beyond Meat, Inc.

Alector, Inc.

Freedom Broker has pointed out the two small-cap stocks with the most pronounced moves last week (October 20-24). The outperformer was plant-based meat producer Beyond Meat, while the underperformer was biopharma company Alector, a developer of therapies for dementia.

Freedom Broker names biggest small cap outperformer and underperformer from last week

Tesla, Inc.

Alphabet Inc.

Keurig Dr Pepper Inc.

Morning in New York: investors are driven by optimism

International Business Machines Corporation

Netflix, Inc.

AT&T Inc.

SAP SE

Amazon.com, Inc.

General Motors Company

RTX Corporation

The Coca-Cola Company

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research

Morning in New York: S&amp;P 500 aims for a new high

DocGo Inc.

Rocket Lab Corporation

Alibaba Group Holding Limited

New York Morning: Reporting season is heating up

DXP Enterprises, Inc.

Freedom Broker has initiated coverage of DXP Enterprises, a leading small-cap provider of engineering solutions for the industrial sector, with a "buy" at a target price that implies upside of 33% versus the current market price. The company has a balanced business model and stable cash flow, Freedom argues.

Freedom says 'buy' on industrial supplier DXP, citing model, M&A, sector outlook

Apple Inc.

Kering SA

Morning in New York: focus on geopolitics and corporate news

Zions Bancorporation, National Association

Stocks are pressured by a combination of three negative factors at once

Morning in New York: the degree of tension in the market is growing

aTyr Pharma, Inc.

Shares of aTyr Pharma, a biotech developer of therapies for pulmonary sarcoidosis, collapsed 83% in a single day on September 15 after the company’s lead drug <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study">failed</a>&nbsp;in a pivotal phase III trial. The candidate, efzofitimod, showed little advantage over placebo in reducing steroid dependence among patients. This marks <a href="https://finance.yahoo.com/news/atyr-shares-plunge-trial-miss-121100328.html">another setback</a> for aTyr, which seven years earlier halted its cancer research program after disappointing preclinical results that cut its market value nearly in half.

#Freedom Holding: 41